The major source of errors producing unreliable laboratory test results is the pre-analytical phasewith hemolysis accounting for approximately half of themand being the leading cause of unsuitable blood specimens. Hemolysis may produce interference in many laboratory tests by a variety of biological and analytical mechanisms. Consequently, laboratories need to systematically detect and reliably quantify hemolysis in every collected sample by means of objective and consistent technical tools that assess sample integrity. This is currently done by automated estimation of hemolysis index (HI), available on almost all clinical chemistry platforms, making the hemolysis detection reliable and reportable patient test results more accurate. Despite these advantages, a degree of variability still affects the HI estimate and more efforts should be placed on harmonization of this index. The harmonization of HI results from different analytical systems should be the immediate goal, but the scope of harmonization should go beyond analytical steps to include other aspects, such asHI decision thresholds, criteria for result interpretation and application in clinical practice as well as report formats.With regard to this, relevant issues to overcome remain the objective definition of a maximum allowable bias for hemolysis interference based on the clinical application of the measurements and the management of unsuitable samples. Particularly, for the latter a recommended harmonized approach is required when not reporting numerical results of unsuitable sampleswith significantly increasedHI and replacing the test resultwith a specific comment highlighting hemolysis of the sample.
Harmonization of automated hemolysis index assessment and use: is it possible? / A. Dolci, M. Panteghini. - In: CLINICA CHIMICA ACTA. - ISSN 0009-8981. - 432(2014), pp. 38-43. [10.1016/j.cca.2013.10.012]
Harmonization of automated hemolysis index assessment and use: is it possible?
A. Dolci;M. Panteghini
2014
Abstract
The major source of errors producing unreliable laboratory test results is the pre-analytical phasewith hemolysis accounting for approximately half of themand being the leading cause of unsuitable blood specimens. Hemolysis may produce interference in many laboratory tests by a variety of biological and analytical mechanisms. Consequently, laboratories need to systematically detect and reliably quantify hemolysis in every collected sample by means of objective and consistent technical tools that assess sample integrity. This is currently done by automated estimation of hemolysis index (HI), available on almost all clinical chemistry platforms, making the hemolysis detection reliable and reportable patient test results more accurate. Despite these advantages, a degree of variability still affects the HI estimate and more efforts should be placed on harmonization of this index. The harmonization of HI results from different analytical systems should be the immediate goal, but the scope of harmonization should go beyond analytical steps to include other aspects, such asHI decision thresholds, criteria for result interpretation and application in clinical practice as well as report formats.With regard to this, relevant issues to overcome remain the objective definition of a maximum allowable bias for hemolysis interference based on the clinical application of the measurements and the management of unsuitable samples. Particularly, for the latter a recommended harmonized approach is required when not reporting numerical results of unsuitable sampleswith significantly increasedHI and replacing the test resultwith a specific comment highlighting hemolysis of the sample.File | Dimensione | Formato | |
---|---|---|---|
2014 CCA HI standardization.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
417.63 kB
Formato
Adobe PDF
|
417.63 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.